American Autoimmune Related Diseases Association Issues Statement on Insurance Incentives

DETROIT – The American Autoimmune Related Diseases Association (AARDA), the world’s leading nonprofit organization dedicated to autoimmune awareness, advocacy, education, and research, issued a statement regarding health insurance incentives:

"Biosimilars play a vital role in treating patients with complex and costly conditions. However, AARDA remains concerned by the increased role Cigna and other health insurance companies are taking to interfere in the patient-clinician treatment decision by attempting to bribe patients to switch from one medicine to another. We are in full support of cost savings to patients, but these should come at the pharmacy counter after the patient and physician collectively decide on a treatment plan. At a time when many are under financial duress, the financial enticement by an insurance company making a purely business decision, not involved with actual care in any way, could interfere with the patient’s health outcomes. We believe there’s a better way to provide cost savings without harming patients, which must be based on putting the interests of patients and providers first.”

AARDA collaborates to transform the lives of those affected by autoimmune disease, ensuring they are empowered to achieve a timely diagnosis, access cutting-edge treatment, and someday, discover a cure.

# # #

About AARDA
American Autoimmune Related Diseases Association (AARDA) is the nation’s only nonprofit organization dedicated to bringing a national focus to autoimmunity as a category of disease and a major women’s health issue and promoting a collaborative research effort in order to find better treatments and a cure for all autoimmune diseases.

For upcoming AARDA events visit Events Calendar at www.aarda.org. For more information, visit www.aarda.org. Follow us on social media: Facebook, Twitter, LinkedIn, Instagram, and YouTube.